🚀 VC round data is live in beta, check it out!
Dermapharm Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dermapharm Holding and similar public comparables like Jamjoom Pharma, Wockhardt, BioKangtai, Cosmo Pharmaceuticals and more.
Dermapharm Holding Overview
About Dermapharm Holding
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
Founded
1991
HQ
Employees
3.6K
Website
Sectors
Financials (LTM)
EV
$3B
Dermapharm Holding Financials
Dermapharm Holding reported last 12-month revenue of $1B and EBITDA of $378M.
In the same LTM period, Dermapharm Holding generated $378M in EBITDA and $142M in net income.
Revenue (LTM)
Dermapharm Holding P&L
In the most recent fiscal year, Dermapharm Holding reported revenue of $1B and EBITDA of $373M.
Dermapharm Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $890M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $378M | XXX | $373M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $142M | XXX | $132M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $976M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dermapharm Holding Stock Performance
Dermapharm Holding has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
Dermapharm Holding's stock price is $45.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | (0.2%) | XXX | XXX | XXX | $2.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDermapharm Holding Valuation Multiples
Dermapharm Holding trades at 2.5x EV/Revenue multiple, and 9.0x EV/EBITDA.
EV / Revenue (LTM)
Dermapharm Holding Financial Valuation Multiples
As of March 7, 2026, Dermapharm Holding has market cap of $2B and EV of $3B.
Equity research analysts estimate Dermapharm Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dermapharm Holding has a P/E ratio of 17.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBIT | 12.7x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.8x | XXX | XXX | XXX |
| P/E | 17.2x | XXX | 18.5x | XXX | XXX | XXX |
| EV/FCF | 17.2x | XXX | 18.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dermapharm Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dermapharm Holding Margins & Growth Rates
Dermapharm Holding's revenue in the last 12 month grew by 4%.
Dermapharm Holding's revenue per employee in the last FY averaged $0.4M.
Dermapharm Holding's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dermapharm Holding's rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Dermapharm Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dermapharm Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jamjoom Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Wockhardt | XXX | XXX | XXX | XXX | XXX | XXX |
| BioKangtai | XXX | XXX | XXX | XXX | XXX | XXX |
| Cosmo Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocular Therapeutix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dermapharm Holding M&A Activity
Dermapharm Holding acquired XXX companies to date.
Last acquisition by Dermapharm Holding was on XXXXXXXX, XXXXX. Dermapharm Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dermapharm Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDermapharm Holding Investment Activity
Dermapharm Holding invested in XXX companies to date.
Dermapharm Holding made its latest investment on XXXXXXXX, XXXXX. Dermapharm Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dermapharm Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dermapharm Holding
| When was Dermapharm Holding founded? | Dermapharm Holding was founded in 1991. |
| Where is Dermapharm Holding headquartered? | Dermapharm Holding is headquartered in Germany. |
| How many employees does Dermapharm Holding have? | As of today, Dermapharm Holding has over 3K employees. |
| Is Dermapharm Holding publicly listed? | Yes, Dermapharm Holding is a public company listed on LSE International. |
| What is the stock symbol of Dermapharm Holding? | Dermapharm Holding trades under 0A5J ticker. |
| When did Dermapharm Holding go public? | Dermapharm Holding went public in 2020. |
| Who are competitors of Dermapharm Holding? | Dermapharm Holding main competitors are Jamjoom Pharma, Wockhardt, BioKangtai, Cosmo Pharmaceuticals. |
| What is the current market cap of Dermapharm Holding? | Dermapharm Holding's current market cap is $2B. |
| What is the current revenue of Dermapharm Holding? | Dermapharm Holding's last 12 months revenue is $1B. |
| What is the current revenue growth of Dermapharm Holding? | Dermapharm Holding revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Dermapharm Holding? | Current revenue multiple of Dermapharm Holding is 2.5x. |
| Is Dermapharm Holding profitable? | Yes, Dermapharm Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dermapharm Holding? | Dermapharm Holding's last 12 months EBITDA is $378M. |
| What is Dermapharm Holding's EBITDA margin? | Dermapharm Holding's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Dermapharm Holding? | Current EBITDA multiple of Dermapharm Holding is 9.0x. |
| What is the current FCF of Dermapharm Holding? | Dermapharm Holding's last 12 months FCF is $198M. |
| What is Dermapharm Holding's FCF margin? | Dermapharm Holding's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Dermapharm Holding? | Current FCF multiple of Dermapharm Holding is 17.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.